慢性肝病患者相关骨病的研究进展

摘要/Abstract

摘要： 骨质疏松症是慢性肝病患者常见的并发症,特别是肝硬化、胆汁淤积性肝病以及接受肝移植的患者。免疫细胞活化、慢性炎症以及肠道菌群会影响骨质疏松症的进展,慢性肝病患者需要特殊关注:肝硬化、肝癌、胆汁淤积性肝病、酒精性肝病、脂肪肝、肝移植后均易影响骨的代谢,导致骨质疏松相关的问题。慢性肝病患者的肌少症、髋关节缺血坏死均与骨代谢相关。现就慢性肝病患者并发骨疾病的诊疗指南、发病机制,以及慢性肝病患者的骨疾病的研究现状作一综述。

关键词: 骨质疏松, 肝病, 肝硬化, 胆汁淤积性肝病, 肝移植, 酒精性肝病, 少肌症

郭蕊, 崔莹, 王诗美, 樊微微, 胡晓丽. 慢性肝病患者相关骨病的研究进展[J]. 肝脏, 2022, 27(6): 711-715.

参考文献

[1] Nuti R, Brandi ML, Checchia G, et al. Guidelines for the management of osteoporosis and fragility fractures. Intern Emerg Med, 2019, 14(1): 85-102.
[2] European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Liver transplantation. J Hepatol, 2016, 64(2): 433-485.
[3] Compston JE, Mcclung MR, Leslie WD. Osteoporosis. Lancet, 2019, 393(10169): 364-376.
[4] Cao X. RANKL-RANK signaling regulates osteoblast differentiation and bone formation. Bone Res, 2018, 6: 35.
[5] Bang CS, Shin IS, Lee SW, et al. Osteoporosis and bone fractures in alcoholic liver disease: a meta-analysis. World J Gastroenterol, 2015, 21(13): 4038-4047.
[6] Blaschke M, Koepp R, Cortis J, et al. IL-6, IL-1β, and TNF-α only in combination influence the osteoporotic phenotype in Crohn’s patients via bone formation and bone resorption. Adv Clin Exp Med, 2018, 27(1): 45-56.
[7] Zhao B, Grimes SN, Li S, et al. TNF-induced osteoclastogenesis and inflammatory bone resorption are inhibited by transcription factor RBP-J. J Exp Med, 2012, 209(2): 319-334.
[8] Das M, Cronin O, Keohane DM, et al. Gut microbiota alterations associated with reduced bone mineral density in older adults. Rheumatology (Oxford), 2019, 58(12): 2295-2304.
[9] Loria I, Albanese C, Giusto M, et al. Bone disorders in patients with chronic liver disease awaiting liver transplantation. Transplant Proc, 2010, 42(4): 1191-1193.
[10] Monegal A, Navasa M, Gua?abens N, et al. Bone disease after liver transplantation: a long-term prospective study of bone mass changes, hormonal status and histomorphometric characteristics. Osteoporos Int, 2001, 12(6): 484-492.
[11] Huldén E, Castedal M, Karlsson MK, et al. Osteoporosis in cirrhotics before and after liver transplantation: relation with malnutrition and inflammatory status. Scand J Gastroenterol, 2020, 55(3): 354-361.
[12] Martin P, Dimartini A, Feng S, et al. Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology, 2014, 59(3): 1144-1165.
[13] Chen CH, Lin CL, Kao CH. Association Between Chronic Hepatitis B Virus Infection and Risk of Osteoporosis: A Nationwide Population-Based Study. Medicine (Baltimore), 2015, 94(50): e2276.
[14] Grigsby IF, Pham L, Mansky LM, et al. Tenofovir-associated bone density loss. Ther Clin Risk Manag, 2010, 6: 41-47.
[15] Komatsu A, Ikeda A, Kikuchi A, et al. Osteoporosis-Related Fractures in HIV-Infected Patients Receiving Long-Term Tenofovir Disoproxil Fumarate: An Observational Cohort Study. Drug Saf, 2018, 41(9): 843-848.
[16] Grant PM, Cotter AG. Tenofovir and bone health. Curr Opin HIV AIDS, 2016, 11(3): 326-332.
[17] Handzlik-Orlik G, Holecki M, Wilczyński K, et al. Osteoporosis in liver disease: pathogenesis and management. Ther Adv Endocrinol Metab, 2016, 7(3): 128-135.
[18] Danford CJ, Trivedi HD, Papamichael K, et al. Osteoporosis in primary biliary cholangitis. World J Gastroenterol, 2018, 24(31): 3513-3520.
[19] Liao CY, Chung CH, Chu P, et al. Increased risk of osteoporosis in patients with primary biliary cirrhosis. PLoS One, 2018, 13(3): e0194418.
[20] Hay JE. Bone disease in cholestatic liver disease. Gastroenterology, 1995, 108(1): 276-283.
[21] González-Reimers E, Quintero-Platt G, Rodríguez-Rodríguez E, et al. Bone changes in alcoholic liver disease. World J Hepatol, 2015, 7(9): 1258-1264.
[22] Zheng JP, Miao HX, Zheng SW, et al. Risk factors for osteoporosis in liver cirrhosis patients measured by transient elastography. Medicine (Baltimore), 2018, 97(20): e10645.
[23] Chen DZ, Xu QM, Wu XX, et al. The Combined Effect of Nonalcoholic Fatty Liver Disease and Metabolic Syndrome on Osteoporosis in Postmenopausal Females in Eastern China. Int J Endocrinol, 2018, 2018: 2314769.
[24] Uchida S, Miyaaki H, Ichikawa T, et al. Risk factors for osteoporosis in patients with end-stage liver disease. Biomed Rep, 2016, 5(5): 629-633.
[25] Kim G, Kim KJ, Rhee Y, et al. Significant liver fibrosis assessed using liver transient elastography is independently associated with low bone mineral density in patients with non-alcoholic fatty liver disease. PloS one, 2017, 12(7): e0182202.
[26] Kovalic AJ, Cholankeril G, Satapathy SK. Nonalcoholic fatty liver disease and alcoholic liver disease: metabolic diseases with systemic manifestations. Transl Gastroenterol Hepatol, 2019, 4:65.
[27] Bering T, Diniz KGD, Coelho MPP, et al. Association between pre-sarcopenia, sarcopenia, and bone mineral density in patients with chronic hepatitis C. J Cachexia Sarcopenia Muscle, 2018, 9(2): 255-268.
[28] Bansal RK, Kumar M, Sachdeva PR, et al. Prospective study of profile of hepatic osteodystrophy in patients with non-choleastatic liver cirrhosis and impact of bisphosphonate supplementation. United European Gastroenterol J, 2016, 4(1): 77-83.
[29] Ormsbee MJ, Prado CM, Ilich JZ, et al. Osteosarcopenic obesity: the role of bone, muscle, and fat on health. J Cachexia Sarcopenia Muscle, 2014, 5(3): 183-192.
[30] Hung TH, Hsieh YH, Tsai CC, et al. Is liver cirrhosis a risk factor for osteonecrosis of the femoral head in adults? A population-based 3-year follow-up study. Intern Med, 2011, 50(21): 2563-2568.
[31] Shah NL, Caldwell SH. Assessing the risk of bleeding and clotting in cirrhosis. Clin Liver Dis (Hoboken), 2016, 7(2): 26-28.
[32] Guañabens N, Parés A. Liver and bone. Arch Biochem Biophys, 2010, 503(1): 84-94.
[33] Bolland MJ, Leung W, Tai V, et al. Calcium intake and risk of fracture: systematic review. BMJ, 2015, 351: h4580.
[34] Malnick S, Maor Y, Melzer E, et al. Severe hepatocytotoxicity linked to denosumab. Eur Rev Med Pharmacol Sci, 2017, 21(1 Suppl): 78-85.